MétaCan
Menu
Back to cohort
Record W4367155480 · doi:10.18053/jctres.09.202303.003

The dietary supplement Cyplexinol® alleviates joint pain in men and women

2023· article· en· W4367155480 on OpenAlexaboutno aff
Jacquelyn Pence, Michelle B. Stockton, Richard J. Bloomer

Bibliographic record

VenueJournal of Clinical and Translational Research · 2023
Typearticle
Languageen
FieldMedicine
TopicBone health and osteoporosis research
Canadian institutionsnot available
FundersUniversity of Memphis
KeywordsMedicinePlaceboWOMACOsteoarthritisVisual analogue scaleJoint painPhysical therapyMoodInternal medicineChronic pain

Abstract

fetched live from OpenAlex

Background and aim: Joint pain afflicts millions of adults worldwide. The effect of a Bone Morphogenetic Protein Complex on joint pain is assessed in this study. Methods: We compared the impact of a dietary supplement protein complex (Cyplexinol®) and placebo in 18 men and women (aged 43±10 years) with self-reported joint pain. Subjects were randomly assigned to each condition, consumed twice daily for 14 days (900 mg per day). Subjects completed questionnaires (e.g., WOMAC and subjective pain using a visual analog scale [VAS]) at the start and end of each treatment phase. Blood samples were analyzed for bone morphogenic protein (BMP), alkaline phosphatase, and cytokines (TNF-α, IL-6, IL-10, IL-1β, and TGF-β). Blood was also collected on days 1 and 15 to determine the acute impact of treatment on these measures. Results: Pain and discomfort scores improved (p≤0.05) for subjects following use of Cyplexinol® but not placebo. Improvements were noted for WOMAC pain (p=0.05), stiffness (p=0.039), and total pain (p=0.026), as well as VAS pain (p=0.015), recreational activity interference (p=0.023), mood interference (p=0.012), and total pain (p=0.024). A trend was noted for WOMAC physical function (p=0.052). An approximate 50% increase in BMP5 was noted following Cyplexinol® (p=0.01), with a similar increase noted for placebo (p=0.022). A near doubling in TGF-β (p=0.001) was noted for Cyplexinol®. No other changes of significance were noted across time, nor were any differences noted in cytokines following acute intake of the conditions (p>0.05). Conclusions: Cyplexinol® can alleviate joint pain in middle-aged men and women, while elevating BMP5. Cyplexinol® does not influence cytokines, at least within a short two-week supplementation period or within the two-hour post-ingestion period. Relevance for Patients: Individuals suffering with joint pain in the knee and/or hip may benefit from daily use of Cyplexinol®, as we observed decreased pain and stiffness following treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.015

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.323
GPT teacher head0.532
Teacher spread0.209 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical and Translational ResearchSame topicBone health and osteoporosis researchFrench-language works237,207